Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, canakinumab (Ilaris®) cannot be endorsed for use within NHS Wales as monotherapy or in combination with methotrexate for the treatment of active Still's disease including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. |
||
|
||
Medicine details |
||
| Medicine name | canakinumab (Ilaris®) | |
| Formulation | 150 mg powder for solution for injection | |
| Reference number | 1209 | |
| Indication | Monotherapy or in combination with methotrexate for the treatment of active Still's disease including Adult-Onset Still's Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 14/03/2017 | |